As government agencies partner with industry in a race to save countless lives in a growing Ebola outbreak, two hurdles loom large for companies lining up for the run.
Ever since Gilead Sciences Inc. unveiled its $84,000 price tag for Solvaldi, a breakthrough hepatitis C drug, many lawmakers, patient groups and payers have been throwing warning flags about the escalating price of drugs. more »
- Seeking transparency, HHS, NIH suggest major changes in reporting trial data
- Congress sweetening the pot for development of Ebola therapies
- ABPI: Changes needed to advance a stratified medicine approach
- Influenza drug targets become crystal clear
- Post Viehbacher exit, Sanofi sets out its stall on late-stage pipeline
- Beigene adds $75M to help fund early stage oncology candidates
- Hualan moves into biosimilars with plans to start four MAbs trials
- Falling sales of old drugs push Japan's pharmas to focus on new candidates
- Long-term investment needed in China's clinical trial ecosystem
- Suzhou Connect starts phase I trials for S1P1 mo...
Checkpoint inhibitors (CIs) are among the hottest tickets in biopharma, with a handful of deals this year showing that no respectable oncology pipeline can be without one. Combined with traditional chemotherapy and radiation treatment, CIs made a big first impression in metastatic melanoma, thanks to the early success of Yervoy (ipilimumab, Bristol-Myers Squibb Co.).
In humans, norovirus is known to many a traveler as the cruise ship virus which causes gastrointestinal disease. In mice, however, it is a harmless denizen of the gut that does not usually cause overt disease in the animals.
- Metformin shows promise as an adjunctive TB therapy »
- Influenza drug targets become crystal clear »
- Adaptability of enterics may prove key to new treatments, study says »
- Neutralizing siRNA backbone could solve delivery woes »
- Activating antibacterial defense cures viral infection »
- SPHINX solves the riddle of how to block angiogenesis »
- Gene discovery clue to infertility treatments »
- Vaccine may be on the horizon for hepatitis C »
- Study reveals potential pathway for diabetes and obesity treatment »
- Death and taxes: Is the corporate tax rate killing the U.S. economy?October 24, 2014 | 2:54 PM | Posted by: Ann Duncan
- A shot in the dark? ‘Flu’ Manchu-type fears of evil pharma, plus frets over strains and safety, keep too many away from vaccineOctober 07, 2014 | 10:22 PM | Posted by: Randy Osborne
- Emerging biosimilar market knows no parallelSeptember 29, 2014 | 6:15 PM | Posted by: Mari Serebrov
- Ebola is raging like a wildfireSeptember 18, 2014 | 3:32 PM | Posted by: Mari Serebrov
- Balancing innovation and access: The policy conundrumSeptember 15, 2014 | 7:20 PM | Posted by: Jennifer Boggs
Partners in Focus
We can’t say this is going to be [a successful effort], but we think it’s going to be a very interesting conversation.
Cast Your Vote
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter